Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers

Improved Treatment Outcomes by Using Patient Specific Drug Combinations in Mammalian Target of Rapamycin Activated Advanced Metastatic Cancers

Background: Activation of the mTOR signaling pathway is ubiquitous in cancers and a favourable therapeutic target. However, presently approved mTOR inhibitor monotherapies have modest benefits in labeled indications while poor outcomes have been reported for mTOR inhibitor monotherapy when administe...

Full description

Bibliographic Details
Main Authors: Timothy Crook, Darshana Patil, Andrew Gaya, Nicholas Plowman, Sewanti Limaye, Anantbhushan Ranade, Amit Bhatt, Raymond Page, Dadasaheb Akolkar
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
encyclopedic tumor analysis
ETA
mTOR
PIK3CA
PI3K
Akt
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.631135/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.631135/full

Similar Items